HealthDay News — For men with large prostates, the Aquablation procedure is safe, with durable efficacy, according to a study published online April 28 in The Journal of Urology.
Naeem Bhojani, MD, from the University of Montreal, and colleagues reported five-year safety and efficacy outcomes of the Aquablation procedure for treatment of symptomatic benign prostatic hyperplasia and large-volume prostate glands. Data were included for 101 men with moderate-to-severe benign prostatic hyperplasia symptoms and prostate volumes between 80 and 150mL (mean volume at baseline, 107mL), who underwent a robotic-assisted Aquablation procedure.
The researchers found that the study successfully met its safety and efficacy performance goal at 3 months, which was based on transurethral resection of the prostate outcomes typically done in smaller prostates. A significant improvement was seen in patient symptoms, with a change of 15.9 in the International Prostate Symptom Score (from 22.6 at baseline to 6.8 at 5 years). Improvement was also demonstrated in the mean maximum urinary flow rate, from 8.6 to 17.1mL/s at baseline and 5 years, respectively (change, 9.2mL/s). No difference was seen in efficacy outcomes through 5 years in a prespecified subgroup analysis using a baseline prostate volume cutoff of 100mL. At 5 years, freedom from a secondary benign prostatic hyperplasia procedure was 96.3%.
“With real-time ultrasound guidance and robotic execution, Aquablation has the potential to treat prostates of nearly any size,” the authors write. “The five-year data validate the durability of Aquablation.”
Several authors disclosed ties to PROCEPT BioRobotics, which funded the clinical study.